Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/275—Nitriles; Isonitriles
  • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/05—Dipeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
  • C12Q1/18—Testing for antimicrobial activity of a material
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
  • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to MEK inhibitor, p38 inhibitor and/or N FKB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone.
• an in vitro test system wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.
• Influenza A viruses are the causative agents of severe respiratory diseases resulting in significant morbidity and mortality. Most of the fatal cases in the course of an influenza virus (IV) infection are actually a result of secondary pneumonia caused by different bacteria, such as Staphylococcus aureus (S. aureus), Streptococcus pneumoniae and Haemophilus influenzae (Morens et al., 2008, Chertow et al., 2013).
• the most striking problems of bacterial co-infection are the suddenly increased pathogenicity (Iwao et al., 2012, Paddock et al., 2012, Parker et al., 2012) and a limited arsenal of potent anti-infectives against the different pathogens.
• the current invention solves this problem in that it proposes a novel anti-infective strategy against IV and S. aureus co-infections by using single drugs. Furthermore, the present invention solves the problem of rapid resistence development of bacteria by providing drug that targets cellular factors rather than the bacterium itself.
• the present invention relates to a M EK inhibitor, p38 inhibitor and/or N FKB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• the present invention relates to a M EK inhibitor, p38 inhibitor and/or N FKB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
• Bacterial co-infections usually occur within the first six days of an IV infection, resulting in even more fulminant illness, pneumonia and higher mortality (Iverson et al., 2011, Chertow et al., 2013). However in some cases bacterial co-infection comes up, when virus-infection already seems to be cleared. For treatment of viral/bacterial co-infections only limited possibilities exist.
• IV as intracellular pathogens, strongly depend on the cellular signaling machinery (Gong et al., 2009, Ludwig, 2009). IV acquired the ability to highjack cellular factors for its own purpose (Ludwig et al.,2003). Furthermore, IV are able to suppress the innate immune response of their hosts. Given these dependencies, cellular virus-supportive functions are most promising candidates for novel antiviral intervention (Ludwig et al., 2003, Ludwig, 2011, Planz, 2013).
• Targeting cellular rather than viral factors prevents the problem of resistance because the pathogen cannot replace the missing cellular function.
• chemical compounds are available and although in an early stage, some of them have entered clinical testing or are even already licensed.
• S. aureus division is host-cell independent. Novel antibacterial alternatives do not target essential gene products elaborated by the pathogen, but inhibit virulence factors during S. aureus infection without killing the bacterium or boosting host immunity (Park et al., 2012). Other strategies prevent colonization of S. aureus in the human host (Park et al., 2012). These compounds also exhibit a lower potential to induce resistance. Recently, there is accumulating evidence that S. aureus also uses cellular signaling for its own benefits during infection (Oviedo- Boyso et al., 2011), but such bacterial-supportive cellular factors have not yet been characterized as targets for antibacterial therapy in detail.
• the present inventors surprisingly observed, that drugs against intracellular signaling factors, such as N FKB, M EK or p38 MAP kinase, that were previously shown to possess anti influenza activity, also exhibit anti S. aureus activity and reduces both viral- and bacterial titers in a coinfection scenario.
• these signaling inhibitors are most promising candidates for the treatment of IV or S. aureus infections alone, but, most importantly also against severe influenza accompanied with bacterial coinfection.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the the bacterial infection is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
• a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the influenza virus infection is mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H 1N 1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1.
• the influenza A virus is H 1N 1.
• the influenza A virus is H3N2, H5N 1 and H7N9.
• the influenza A virus is H3N2, H5N1, H1N1 and H7N9.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
• the M EK inhibitor is selected from the group consisting of U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD- 0325901, GDC-0973, TAK-733, PD98059, ARRY-438162, PF-3644022 and PD184352, preferably AZD8330, GSK-1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY-438162, PF-3644022 and AZD6244, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
• the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571, SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-l,2- dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CM PD-1, EO 1428, JX 401, M L 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pam
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
• the N FKB inhibitor is selected from the group consisting of LASAG (also called LG- ASA), SC75741, MG 132, TPCA-1, PCTC, I M D 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, I KK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, M L-130, Celastrol, Tanshinone MA, H U 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, M L 120B di
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the M EK inhibitor is combined with another M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor; the p38 inhibitor is combined with another p38 inhibitor, the M EK inhibitor and/or the NFKB inhibitor or the N FKB inhibitor is combined with another NFKB inhibitor, the p38 inhibitor and/or the M EK inhibitor.
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium.
• the M EK inhibitor, the p38 inhibitor and/or the N FKB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the influenza virus.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the bacterium.
• the one or more inhibitors targeting the influenza virus is a neuraminidase inhibitor, preferably oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
• the one or more inhibitors targeting the influenza virus is a compound targeting an ion channel protein (M2), preferably amantadine and/or rimantadine.
• M2 ion channel protein
• the one or more inhibitors targeting the influenza virus is a compound targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP, preferably NP blocker Nucleozin or polymerase inhibitor T-705.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the N FKB inhibitor are combined with one or more inhibitors targeting the bacterium.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
• the one or more inhibitor targeting the bacterium is an antibiotic, preferably Gentamicin, ifampicin, Lysosthaphin, Erythromycin, Levofloxacin Vancomycin, Teicoplanin, Penicillin and Oxacillin.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention is in a subject, preferably a vertebrate.
• compositions comprising a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor for use in a method for the prophylaxis and/or treatment of a co- infection comprising a bacterial infection and an influenza virus infection.
• the composition further comprises a carrier.
• the present invention also relates to a composition, comprising a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
• the composition further comprises a carrier.
• compositions comprising a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• the composition further comprises a carrier.
• the present invention also relates to a composition, comprising a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor and one or more inhibitors targeting the bacterium for use in a method for the prophylaxis and/or treatment of a a bacterial infection.
• the composition further comprises a carrier.
• the M EK inhibitor, p38 inhibitor and/or N FKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
• the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the N FKB inhibitor reduces the bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with a bacterium, when compared to the in vitro test system before the contacting.
• the present invention also relates to an in vitro test system, wherein the test system comprises cultured cells infected with a) an influenza virus and b) a bacterium.
• the invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection.
• the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
• the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting.
• the present invention also provides for an in vitro test system, wherein the in vitro test system comprises cultured cells infected with a bacterium.
• the present invention in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection.
• the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease.
• Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting.
• the present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium.
• Also provided for is a cultured cell infected with a bacterium.
• Fig. 1 Time scale of co-infection procedure. Cells were infected with IV for 30 min. Co-infection with S. aureus 6850 was conducted or cells were mock-treated. Extracellular bacteria were lysed and removed by antibiotic treatment 3 h post bacterial infection. After a PBS wash, cells were supplemented with fresh medium (DMEM/INV) and incubated up to 18 hrs of viral infection
• Fig. 2 The MEK inhibitor U0126 reduces IV titers (A/Puerto Rico/8/34) and S. aureus load, even in a co-infection situation.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DMEM [10% FCS].
• IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B,D).
• CFU colonie forming units
• aureus in presence of 50 ⁇ U0126 results in reduced bacterial titers 18 hrs upon incubation in comparison to DMSO treated bacteria.
• a defined amount of S. aureus 6850 suspension culture was diluted in DM EM/INV supplemented with 50 ⁇ U0126 or DMSO and incubated at 37°C for 18 hrs. Bacteria were diluted and determined by serial dilution on agar plates. Data represent the means ⁇ SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001).
• Fig. 3 The M EK inhibitor U0126 reduces IV titers (A/FPV/Bratislava/79) and S. aureus load, even in a co-infection situation.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DMEM [10% FCS].
• IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D).
• Data represent the means ⁇ SD of two independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; ** p ⁇ 0.01; ** * p ⁇ 0.001).
• Fig. 4 The p38 inhibitor SB202190 reduces IV titers and S. aureus load, even in a co-infection situation.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DMEM [10% FCS].
• IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml ( B, D).
• Data represent the means ⁇ SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (* p ⁇ 0.05; * * p ⁇ 0.01; * * * p ⁇ 0.001).
• Fig. 5 The NF-kappaB (NFKB) inhibitor LG-ASA reduces IV titers and S. aureus load, even in a co- infection situation.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DM EM [10% FCS].
• IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming untits (CFU)/ml (B, D).
• CFU colonie forming untits
• Fig. 6 The viral neuraminidase inhibitor tamiflu reduces IV replication but enhances S. aureus load.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DMEM [10% FCS].
• Fig. 7 Titers of intracellular S. aureus 6850 are reduced upon LG-ASA treatment.
• Human lung epithelial cells A549) were infected with 0.5MOI S. aureus 6850 DM EM/INV [1% human serum albumin, 25 nmol/l HEPES] for 3h in presence (A, C) and absence (B, D) of the indicated amounts of LG-ASA.
• DM EM/INV 1% human serum albumin, 25 nmol/l HEPES
• Three hours post infection an antibiotic wash was included using DM EM/INVantibiotics [2 ⁇ g/ml lysostaphin (Sigma)] to remove non-internalized bacteria and subsequently cells were supplemented with DMEM/INV containing the indicated amounts of LG-ASA.
• Cell morphology was monitored by light microscopy (A, B) and amounts of internalized bacteria were determined by serial dilution on agar plates 18 hours post infection (C, D).
• Fig. 8 Table 2: p38 inhibitors.
• Fig. 9 Table 3: NFKB inhibitors.
• Fig. 10 Table 4: NFKB inhibitors.
• Fig. 11 Table 5: antibiotics.
• Fig. 12 Time scale of the co-infection procedure in vitro.
• Human lung epithelial cells A549) were infected with influenza A virus (IAV) for 30min at a multiplicity of infection (MOI) indicated, dissolved in PBS/BA [0.2% bovine serum albumin, ImM MgCI 2 , 0.9mM CaCI 2 , lOOU/ml penicillin, O.lmg/ml streptomycin] at 37 °C. After 30min incubation, the virus dilution was aspirated, cells were rinsed with PBS. Afterwards bacterial infection with Staphylococcus aureus 6850 (S. aureus) was performed or cells were mock-treated.
• IAV influenza A virus
• MOI multiplicity of infection
• DM EM/INV 1% human serum albumin, 25nmol/l HEPES
• S. aureus in addition to the indicated amounts of inhibitor (U0126 or CI-1040) or solvent control.
• DM EM, 10%FBS, 2 ⁇ g/ml Lysostaphin or 100 ⁇ g/ml Gentamicin, 20min was introduced to remove non-internalized bacteria.
• Fig. 13 Inhibition of the MEK/E K signaling results in enhanced cell survival after singular and co- infection.
• DMEM/INV containing 1% human serum albumin, 25nM HEPES
• 3hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 ⁇ g/ml lysostaphin for 20min to remove non- internalized bacteria. After an additional wash with PBS cells were supplemented with infection medium DM EM/BA (0.2% BA, ImM MgCI 2 , 0.9mM CaCI 2 , lOOU/ml penicillin, O.lmg/ml streptomycin) containing 50 ⁇ U0126 or solvent. After an incubation period of 18hrs at 37°C cell morphology was monitored by light microscopy.
• Fig. 14 Inhibition of MEK/ERK signaling results in reduced viral titers during singular viral and co- infection.
• DMEM/INV containing 1% human serum albumin, 25nM HEPES
• Fig. 15 MEK inhibition by administration of U0126 results in reduced bacterial growth.
• DMEM/INV containing 1% human serum albumin, 25nM HEPES
• 3hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 ⁇ g/ml lysostaphin for 20min (A, C) to remove non- internalized bacteria.
• DMEM/BA 0.2% BA, ImM MgCI 2 , 0.9mM CaCI 2 , lOOU/ml penicillin, O.lmg/ml streptomycin
• Amounts of internalized bacteria were determined by serial dilution of cell lysates on agar plates 18hrs post infection (A, C). The impact of U0126 on bacterial growth was analyzed by administration of U0126 as indicated to an over-night culture of S.
• DMEM/FBS containing 10% human serum albumin, 100 ⁇ g/ml Gentamicin
• Fig. 17 Administration of U0126 leads to reduced bacterial titers in vivo independent of viral titers.
• 12 weeks old Balb/C mice were infected with 50 PFU of the influenza virus strain A/Puerto Rico/8/34 (PR8, HlNl) on day 0 (anesthesized with Isoflurane). Starting on day 1 mice were treated daily with i.p. injection of 30mg/kg/day U0126 or solvent control (10% DMSO, 30% Cremophor EL, 60% PBS). On day 3 mice were infected with 5*10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane and directly treated with U0126 or solvent control.
• Fig. 18 The specific M EK inhibitor CI-1040 reduces viral titers in singular and co-infection.
• Human lung epithelial cells (A549) were infected with the avian influenza virus strain
• After 30min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25nM HEPES) with or without S. aureus 6850 (MOI 0.1) in presence of 10 ⁇ CI-1040 or solvent control. 3hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 ⁇ g/ml lysostaphin for 20min to remove extracellular bacteria.
• CI-1040 The impact of CI-1040 on bacterial growth was analyzed by administration of CI-1040 in different concentrations (as indicated) to an over-night culture of S. aureus 6850 (100 CFU/ml). After 16hrs serial dilutions were plated on BHI agar (A, B). Bacterial titers are depicted as colony forming units/ml (CFU/ml) with a linear (A) or logarithmic scale (B). Data represent preliminary data with two biological samples.
• Fig. 20 Treatment with the specific M EK inhibitor Cobimetinib (GDC-0973) reduces pathogen load in vivo.
• mice 8 weeks old Balb/C mice (5 per group) were infected with 50 PFU of influenza virus strain A/Puerto Rico/8/34 (PR8, H1N1) on day 0 (anesthesized with Isoflurane). 6hrs post viral infection mice were treated with oral administration of lOmg/kg/day Cobimetinib or solvent control (10% DMSO, 5% Tween 20, 85% PBS). Treatment was then performed daily. On day 3 mice were infected with 5*10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane and 6hrs later treated with Cobimetinib or solvent control. On day 4 lungs were removed and homogenized in PBS (O.lg per 1000 ⁇ PBS).
• Fig. 21 LG-ASA improves cell morphology upon infection with influenza A virus (IAV) and/or Staphylococcus aureus (S. aureus)
• 3hrs post bacterial infection cells were treated with antibiotics [DM EM, 10%FBS, 2 ⁇ g/ml lysostaphin, 20min] to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5mM LG-ASA or solvent. After an incubation period of 18hrs at 37°C cell morphology was monitored by light microscopy.
• antibiotics [DM EM, 10%FBS, 2 ⁇ g/ml lysostaphin, 20min] to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5mM LG-ASA or solvent. After an incubation period of 18hrs at 37°C cell morphology was monitored by light microscopy.
• MOI multiplicity of infection
• Fig. 23 The NFKB inhibitor LG-ASA reduces influenza virus titers and S. aureus load
• Fig. 25 Stimulation of N FKB signaling results in enhanced bacterial internalization
• Fig. 26 Treatment of IAV/S. aureus co-infected mice with LG-ASA results in enhanced survival and reduced body weight loss
• mice 4 mice per group were infected with 50 PFU of the influenza virus A/Puerto Rico/8/34 at day 0. On day 6 after influenza virus infection mice were additionally infected with 10 8 CFU S. aureus 6850. On day 7 after influenza virus infection co-infected mice were treated once a day with LG-ASA (1M, lOmin) via inhalation. Survival was monitored for 14 days.
• mice Two independent experiments are depicted. 9 weeks old Balb/C mice (4 mice per group) were infected with 50 PFU of influenza virus A/Puerto Rico/8/34 on day 0 (anesthesized with Isoflurane) in the morning. 6hrs post viral infection mice were weighed and treated with aerosolic H 2 0 or 1M LG-ASA in an inhalation chamber for lOmin. This treatment was also performed on day 1, 2 and 3 at the same time as on day 0. On day 3 in the morning mice were infected with 5* 10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane. On day 4 mice were weighed the last time. Statistical analysis was done using Mann-Whitney U Test (* p ⁇ 0.05). DETAILED DESCRIPTION OF THE INVENTION/DETAILED DESCRIPTION OF A PREFERENTIAL
• the present invention relates to a M EK inhibitor, p38 inhibitor and/or NFKB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• M EK inhibitor a M EK inhibitor, p38 inhibitor and/or NFKB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
• M EK inhibitor may also be designated as a Mitogen Activated Proteinkinase (MAPK) kinase inhibitor.
• MAPK Mitogen Activated Proteinkinase
• M EK inhibitors of the invention preferably inhibit M EK1/2 of a subject, such as a mammal or bird as described herein.
• a M EK inhibitor of the invention does not only inhibit a M EK, preferably M EK1/2, but also its upstream kinase (i.e. MAPKKK), thereby exerting a dual inhibition.
• PLX-4032 may be such a dual inhibitor.
• a M EK inhibitor of the invention may in a preferred aspect by a dual inhibitor, thereby inhibiting a M EK, preferably M EK1/2 and the corresponding upstream MAPKKK.
• M EK1/2 is the MAPKK in the as/ af pathway, whereby Ras/Raf acts as MAPKKK and ERK1/2 acts as MAPK.
• a M EK inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
• the M EK inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
• M EK inhibitor is a pharmaceutically acceptable salt of the M EK inhibitor. The determination of whether or not a compound is a M EK inhibitor is within the skill of one of ordinary skill in the art.
• the M EK inhibitors are selected from the group consisting of the compounds/inhibitors listed in table 1.
• the M EK inhibitors of the invention are selected preferably from U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, PD98059, PD184352 ARRY-438162 and PF-3644022, preferably AZD8330, GSK- 1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY-438162, PF-3644022 and AZD6244 and most preferably U0126, CI-1040, GDC-0973 (Cobimetinib), AZD8330, GSK-1120212, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
• PLX-4032 AZD6244, AZD8330, GDC-0973, DEA119, GSK1120212, R051267766, R04987655, TAK-733, and AS703026. Even more preferably, they are selected from AZD6244, AZD8330, GSK1120212 and PLX-4032 or from PD-0325901, AZD-6244, AZD-8330 and RDEA-119.
• MEK inhibitors are known in the art and, for example, described in Table 1 of Fremin and Meloche (2010), J. Hematol. Oncol. 11;3:8.
• CI-1040 disclosed herein show an effect in co-infection scenarios as well as on bacterial infection alone.
• a p38 inhibitor is provided for use in the methods for the prophylaxis and/or treatment of a co- infection or bacterial infection of the present invention.
• a "p38 MAP kinase inhibitor” is well known in the art.
• the terms “p38 inhibitor,” “p38 kinase inhibitor,” and “p38 MAP kinase inhibitor” are used interchangeably herein.
• a p38 MAP kinase inhibitor inhibits p38 MAP kinase.
• the p38 MAP kinase inhibitor inhibits one of the isoforms of p38 MAP kinase, preferably one of the four isoforms ( ⁇ , ⁇ , ⁇ or ⁇ ) of p38 MAP kinase with the a-isoform being preferred, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase and most preferably, it inhibits all isoforms or the ⁇ , ⁇ , ⁇ and ⁇ isoform of p38 MAP kinase.
• the p38 MAP kinase inhibitor inhibits the isoform of p38 that is involved in inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, viral diseases or neurodegenerative diseases. It is reported that the ⁇ -isoform of p38 MAP kinase is involved in inflammation, proliferation, differentiation and apoptosis, whereas the biological functions of p38 ⁇ , p38 ⁇ and p38 ⁇ are not yet understood completely. Accordingly, it is preferred herein that the p38 MAP kinase inhibitor inhibits the a-isoform.
• a p38 MAP kinase inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
• the p38 MAP kinase inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
• Also included by the term p38 inhibitor is a pharmaceutically acceptable salt of the 38 inhibitor.
• Another p38 MAP kinase inhibitor is BI B 796 BS (l-(5-tert-butyl-2-p- tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-l-yl]-urea); see Branger (2002), J. Immunol. 168:4070-4077 or US 6,319,921 for further p39 MAP kinase inhibitors.
• p38 MAP kinase inhibitors are AMG 548 (Amgen), BIRB 796 (Boehringer Ingelheim), VX 702 (Vertex/Kissei), SCIO 469, SCIO 323 (Scios Inc.), SB 681323 (GlaxoSmithKline), PH-797804 (Pfizer) and Org-48762-0 (Organon NV); see, for example, Lee and Dominguez in Curr Med Chem. 2005;12(25):2979-2994 and Dominguez in Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-430.
• the inhibitor may exhibit its regulatory effect upstream or downstream of p38 MAP kinase or on p38 MAP kinase directly, with the latter mode of action being preferred.
• inhibitor regulated p38 MAP kinase activity include those where the inhibitor may decrease transcription and/or translation of p38 MAP kinase, may decrease or inhibit post- translational modification and/or cellular trafficking of p38 MAP kinase, or may shorten the half-life of p38 MAP kinase.
• the inhibitor may also reversibly or irreversibly bind p38 MAP kinase, inhibit its activation, inactivate its enzymatic activity, or otherwise interfere with its interaction with downstream substrates.
• an inhibitor of p38 MAP kinase that is specific for the a-isoform of the kinase possesses at least three categories of structural features that are theorized to permit isoform specific inhibition.
• Selective binding of a candidate p38 MAP kinase inhibitor can be determined by a variety of methods.
• the genes for the various isoforms of p38 MAP kinase are known in the art.
• One of ordinary skill in the art could readily clone and express the various isoforms of the kinase, purify them, and then perform binding studies with candidate compounds to determine isoform binding characteristics. This series of experiments was performed for the a-isoform of p38 MAP kinase and provided in U.S. Pat. No. 6,617,324 Bl.
• a p38 MAP kinase inhibitor inhibits one of the four isoforms of p38 MAP kinase, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase, e.g., p38- ⁇ ( ⁇ 14), - ⁇ ( ⁇ ), - ⁇ (MAPK12 or ERK6). Alternatively, but also preferred, it inhibits all four isoforms of p38 MAP kinase.
• the p38 inhibitor is selected from the group consisting of the inhibitors listed in table 2 (Fig. 8). In another embodiment, the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571, SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4- (fluorophenyl)-5-pyridin-4-yl-l,2-dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CM PD-1, EO 1428, JX 401, M L 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB68132
• the present invention is also directed to a N FKB (NFkB/N FkappaB) inhibitor for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention.
• N F- ⁇ nuclear factor kappa-light-chain-enhancer of activated B cells
• N F- ⁇ is a protein complex that controls transcription of DNA.
• Vertebrate N FKB transcription complexes can be any of a variety of homo- and heterodimers formed by the subunits p50 (NFKBI), p52 (NFKB2), c- el, RelA (p65) and RelB (Gilmore TD. (2006) Oncogene 25: 6680-6684). These complexes bind to DNA regulatory sites called KB sites, generally to activate specific target gene expression.
• N F- ⁇ dimers are located in the cytoplasm in an inactive form through association with any of several ⁇ inhibitor proteins ( ⁇ ⁇ , ⁇ , ⁇ , ⁇ , pl05 and plOO).
• ⁇ inhibitor proteins ⁇ ⁇ , ⁇ , ⁇ , ⁇ , pl05 and plOO.
• ⁇ ⁇ , ⁇ , ⁇ , pl05 and plOO ⁇ inhibitor proteins
• N FKB complexes which is mediated by the ⁇ kinase (I KK) complex containing two kinase subunits, IKKot and ⁇ , and an associated scaffold-like regulatory protein called N EMO (aka ⁇ )
• N EMO ⁇ kinase
• NF- ⁇ siganling is also important for bacterial (such as S. aureus) internalisation into cells.
• the inhibitor may exhibit its regulatory effect upstream or downstream of NFKB or directly on NFKB, with the latter mode of action being preferred.
• inhibitors regulating NFKB activity include those where the inhibitor may decrease transcription and/or translation of NFKB, or may shorten the half-life of NFKB.
• the inhibitor may also reversibly or irreversibly bind NFKB, inhibit its activation, inactivate its activity, or otherwise interfere with its interaction with downstream targets, such as trgets on genes.
• an NFKB inhibitor can inhibit protein kinases such as molceules which inhibit IkBa phosphorylation by e.g. I KK inhibition.
• NFKB inhibitors may inhibit protein phosphatases, or inhibit the proteasome, or ubiquitination.
• NFKB inhibitors which may also serve as reference compounds include protein tyrosine phosphatase inhibitors, boronate, bortezomib, N PI-0052.
• a N FKB inhibitor may block the nuclear translocation of NFKB, or its binding to DNA. Examples of such inhibitors include, which may also serve as reference compounds, SN50, dehydroxymethylepoxyquinomicin and NFKB decoy ODNs.
• a NFKB inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
• the N FKB inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
• Also included by the term NFKB inhibitor is a pharmaceutically acceptable salt of the NFKB inhibitor.
• the NFKB inhibitor is selected from the group consisting of the inhibitors/molceules as listed in tables 3 and 4 in Figures 9 and 10.
• the N FKB inhibitor is selected from the group consisting of the inhibitors/molceules as listed in table 3 in Figure 9.
• the N FKB inhibitor is selected from the group consisting of the inhibitors/molceules as listed in table 4 in Figure 10.
• the N FKB inhibitor is selected from the group consisting of LASAG, SC75741 (and derivatives), MG 132, TPCA-1, PCTC, I M D 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, I KK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, M L-130, Celastrol, Tanshinone MA, H U 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, M L 120B dihydrochloride, Amlexanox, 9-Methylstreptimidone, N-Stearoyl phytosphingosine, 2-(l,8-naphthyridin-2-y
• SC75741 or “SC75741 (and derivates) in addition to SC75741 also derivates of SC75741 are envisaged by the present invention.
• M EK inhibitor an M EK inhibitor, p38 inhibitor and/or NFKB inhibitor.
• a further example of how one could determine if a compound is a M EK inhibitor and/or p38 inhibitor would be to isolate the M EK and/or p38 NFKB protein.
• the protein can be isolated from cells where the M EK and/or p38 protein is naturally expressed or where it has been overexpressed by means of transfection of an oligonucleotide or infection with a virus that directs the expression of the M EK and/or p38 protein. Additionally, M EK and/or p38 protein can also be expressed recombinantly.
• a person of ordinary skill in the art can measure the activity of the kinase in the presence or absence of a potential M EK and/or p38 inhibitor. If the kinase activity is less in the presence than in the absence of an alleged inhibitor, that inhibitor is a M EK and/or p38, respectively.
• the inhibitor should exhibit an IC50 value of about 5 ⁇ or less, preferably 500 nm or less, more preferably 100 nm or less.
• the inhibitor should exhibit an IC50 value relative to the p38-a isoform that is preferably at least ten fold less than that observed when the same inhibitor is tested against other p38 MAP kinase isoforms in the same or comparable assay. It should be noted that IC50 values are assay dependent and may change from determination to determination. It is more important to look at relative relationships of compounds' IC50 values rather than the exact values themselves.
• IC50 is the concentration of compound which inhibits the enzyme to 50% of the activity as measured in the absence of an inhibitor. IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control. IC50 values are assay dependent and will vary from measurement to measurement. As such, IC50 values are relative values. The values assigned to a particular inhibitor are to be compared generally rather than on an absolute basis. Samples or assays comprising MAP and/or MAPK kinase that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) can be assigned a relative MAP and/or MAPK kinase activity value of 100%.
• MAP and/or MAPK kinase activity value relative to the control is about 80%, optionally 50% or 25-0%.
• Activation of MAP and/or MAPK kinase is achieved when the MAP kinase activity value relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000- 3000% higher.
• Exemplary MAP kinase binding activity assays of the present invention are: a MAP and/or MAPK kinase ligand blot assay (Aymerich et al., Invest Opthalmol Vis Sci.
• the selectivity of the inhibitors may be measured by a kinase selectivity assay is described in Mihara (2008), Br. J. Pharmacol. 154(1):153-164.
• the NFKB inhibitor one can measure for example the gene products (proteins) of target genes of NFKB in a non-treated control cell and compare the expression of these target gene products to a cell, which has been treated with a N FKB Inhibitor.
• Some target genes are described in Oeckinghaus and Ghosh (2009) The NF- ⁇ Family of Transcription Factors and Its Regulation. Cold Spring Harb Perspect Biol. Oct 2009; 1(4): a000034.
• the expression level is reduced, when the cell treated with the inhibitor.
• Other strategies may be to detect IkBa degradation together with p-p65 accumulation and nuclear translocation of NFKB by Westernblot.
• N FKB interactions with DNA of cells not treated with an inhibitor compared to cells that have been treated with an inhibitor may be analysed by using an electrophoretic mobility shift assay (EMSA).
• ESA electrophoretic mobility shift assay
• the inhibitory properties of a molecule can also be analysed by comparing its action to a reference compound.
• a "reference compound” as referred to herein means a compound, which may be used as a positive control for the determination if a molecule has M EK inhibitor, p38 inhibitor and/or N FKB inhibitor properties. As such also any of the inhibitors listed herein may be used as such a reference compound.
• a possible test may be one in which cells, which are e.g. stimulated to activate the M EK, p38 and or N FKB pathway are treated with a reference compound and in parallel e.g. in a different well with a compound of interest.
• the inhibitors of the present invention can be used in a method for treating and/or prophylaxis.
• treating or “treatment” includes administration of a M EK inhibitor, p38 Inhibitor, and/or NFKB inhibitor preferably in the form of a medicament, to a subject suffering from a coinfection comprising a bacterial infection and an influenza virus infection for the purpose of ameliorating or improving symptoms.
• administration of a M EK inhibitor, p38 Inhibitor, and/or NFKB inhibitor preferably in the form of a medicament, to a subject suffering from a bacterial infection for the purpose of ameliorating or improving symptoms.
• the terms “prophylaxis” as used herein refers to any medical or public health procedure whose purpose is to prevent a disease.
• the terms “prevent”, “prevention” and “preventing” refer to the reduction in the risk of acquiring or developing a given condition, namely a coninfection comprising an influenza virus infection and a bacterial infection or a bacterial infection alone.
• a "co-infection" as used herein comprises an influenza virus infection and a bacterial infection.
• Such a coinfection can take place by simultaneous infection of a host e.g. a subject and/or single cell with a bacterium and an influenza virus. It can also be that a host e.g. a subject and/or cell is simultaneously infected with one or more viral particles and one or more bacteria. However, such a coinfection can also take place sequentially. In such a case is firstly infected with one or more viral particles and later in time the same host and/or cell becomes infected with one or more bacteria or vice versa.
• the time period between the two infections can be a time period of at most 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hours, 6 hours, 3 hours, 1.5 hours or at minimum 30 minutes.
• Such a situation may also be a superinfection, in which a second infection is superimposed on an earlier one especially by a different microbial agent of exogenous or endogenous origin that is resistant to the treatment used against the first infection.
• influenza virus infection can be mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1.
• influenza A virus is H1N1.
• influenza A virus is H3N2, H5N1 and H7N9.
• influenza A virus is H3N2, H5N1, H1N1 and H7N9.
• the present invention also relates to a "bacterial infection" which can take place in the setting of a co-infection described above or can occur as the only infection present in a host e.g. a subject and/or cell.
• the bacterial infection can be mediated by any bacterium, preferably it is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
• the bacterial infection is mediated by a bacterium selected from the group consisting of of Staphylococcus, preferably Staphylococcus aureus, methicillin sensitive and methicillin resistant Staphylococcus aureus, Panton-Valentine leukocidin (PVL)-expressing Staphylococcus aureus and/or Streptococcaceae, preferably Streptococcus mitis, Streptococcus pyogenes or Streptococcus pneumonia, Legionella, preferably Legionella pneumophila, Pseudomonas, preferably Pseudomonas aeruginosa, Chlamydophila, preferably Chlamydophila pneumonia, Mycoplasma, preferably Mycoplasma pneumonia, Klebsiella, preferably Klebsiella pneumonia, Moraxella, preferably Moraxella catarrhalis and/or Haemophilus, preferably Haemophilius influenza.
• the bacterium selected from the
• the inhibitors can be combined with each other.
• the M EK inhibitor is combined with another M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor.
• the p38 inhibitor is combined with another p38 inhibitor, the M EK inhibitor and/or the N FKB inhibitor.
• the NFKB inhibitor is combined with another NFKB inhibitor, the p38 inhibitor and/or the M EK inhibitor.
• the term "another inhibitor” is used to clarify that e.g. one M EK inhibitor can also be combined with another M EK inhibitor, while these two M EK inhibitors are not the same.
• the M EK inhiboitor CI-1040 can be combined with the M EK inhibitor GDC-0973. This equally relates to the p38 and N FKB inhibitors.
• the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more additional inhibitors targeting the influenza virus and the bacterium.
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium.
• the M EK inhibitor, the p38 inhibitor and/or the N FKB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium.
• an inhibitor targeting the influenza virus is any inhibitor or medicament effective in influenza therapy.
• Different substances are known to be effective in reducing an influenza infection. Among them are for example neuraminidase inhibitors, compounds targeting an ion channel protein (M 2) and compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP.
• M2 ion channel protein
• NP ion channel protein
• pharmaceutically acceptable salts of these inhibitors are envisoned.
• a “neuraminidase inhibitor” is an antiviral drug targeted at influenza virus, which works by blocking the function of the viral neuraminidase protein, thus preventing the virus from binding to a cell it aims to infect and/or preventing the virus from reproducing by budding from the host cell, since the newly produced viruses cannot bud off from the cell in which they have replicated.
• pharmaceutically acceptable salts of a neuraminidase inhibitor are oseltamivir, zanamivir, peramivir, or a pharmaceutically acceptable salt of any of these substances, such as oseltamivir phosphate, oseltamivir carboxylate, etc.
• neuraminidase inhibitors are oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
• Compounds targeting an ion channel protein (M2) are for example amantadine and/or rimantadine, while compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP are for example the NP blocker Nucleozin or the polymerase inhibitor T-705.
• the MEK inhibitor, p38 inhibitor and/or NFKB inhibitor can be combined with one or more inhibitors targeting the bacterium.
• An inhibitor targeting the bacterium can be any inhibitor effective in reducing bacterial infection.
• a preferred inhibitor, well known to the skilled artesian is an antibiotic.
• Preferred antibiotics can be obtained from table 5 (Fig. 11).
• the antibiotic is selected from the group consisting of the antibiotics as listed in table 5 ( Figure 11).
• the antibiotic is selected from the group consisting of the class of antibiotics as listed in table 5 ( Figure 11).
• the antibiotic is selected from the group consisting of the generic name of the antibiotics as listed in table 5 ( Figure 11).
• the "subject”, which may be treated by the inhibitors or combinations of inhibitors of the present invention preferably, is a vertebrate.
• the term "subject” means an individual in need of a treatment of a co-infection or a bacterial infection alone.
• the subject is a patient suffering from a co-infection or a bacterial infection alone or being at a risk thereof.
• the patient is a vertebrate, more preferably a mammal. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats.
• a mammal is as a human, dog, cat, cow, pig, mouse, rat etc., particularly preferred, it is a human.
• the subject is a human subject, which optionally is more than 1 year old and less than 14 years old; between the ages of 50 and 65, or older than 65 years of age.
• the subject is a human subject, which is selected from the group consisting of subjects who are at least 50 years old, subjects who reside in chronic care facilities, subjects who have chronic disorders of the pulmonary or cardiovascular system, subjects who required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases, renal dysfunction, hemoglobinopathies, or immunosuppression, subjects with less than 14 years of age, subjects between 6 months and 18 years of age who are receiving long-term aspirin therapy, and women who will be in the second or third trimester of pregnancy during the influenza season.
• the M EK inhibitor, p38 inhibitor or NFKB inhibitor as well as the inhibitor targeting the influenza virus and the inhibitor targeting the bacterium may be administered orally, intravenously, intrapleurally, intramuscularly, topically or via inhalation.
• the M EK inhibitor is administered via nasal inhalation or orally.
• the present invention also envisages different compositions.
• the present invention relates to a composition comprising a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• the present invention similarly relates composition comprising a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
• compositions comprising a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• present invention relates to a composition comprising a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor and one or more inhibitors targeting the the bacterium for use in a method for the prophylaxis and/or treatment of a bacterial infection.
• compositions comprising the M EK inhibitor, the p38 inhibitor and/or the N FKB inhibitor and additionally eventually one or more inhibitors targeting the the bacterium and/or one or more inhibitors targeting the influenza virus may be a pharmaceutical composition.
• such compositions further comprise a carrier, preferably a pharmaceutically acceptable carrier.
• the composition can be in the form of orally administrable suspensions or tablets; nasal sprays, sterile injectable preparations (intravenously, intrapleurally, intramuscularly), for example, as sterile injectable aqueous or oleaginous suspensions or suppositories.
• these compositions When administered orally as a suspension, these compositions are prepared according to techniques available in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art.
• these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents, and lubricants known in the art.
• the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
• suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
• the inhibitor or inhibitors are preferably administered in a therapeutically effective amount.
• the pharmaceutical composition for the use of the invention and comprising a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium is administered to a patient which is a mammal or a bird.
• suitable mammals include, but are not limited to, a mouse, a rat, a cow, a goat, a sheep, a pig, a dog, a cat, a horse, a guinea pig, a canine, a hamster, a mink, a seal, a whale, a camel, a chimpanzee, a rhesus monkey and a human, with human being preferred.
• suitable birds include, but are not limited to, a turkey, a chicken, a goose, a duck, a teal, a mallard, a starling, a Northern pintail, a gull, a swan, a Guinea fowl or water fowl to name a few.
• Human patients are a particular embodiment of the present invention.
• the "therapeutically effective amount" for each active compound/inhibitor can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, adverse events, and the like, as will be apparent to a skilled artisan.
• the amount of administration can be adjusted as the various factors change over time.
• the inhibitors, methods and uses described herein are applicable to both human therapy and veterinary applications.
• the compounds described herein, in particular, M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium having the desired therapeutic activity may be administered in a physiologically acceptable carrier to a subject, as described herein.
• the compounds may be formulated in a variety of ways as discussed below.
• the concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt %.
• the agents maybe administered alone or in combination with other treatments.
• Suitable oral formulations can be in the form of tablets, capsules, suspension, syrup, chewing gum, wafer, elixir, and the like.
• Pharmaceutically acceptable carriers such as binders, excipients, lubricants, and sweetening or flavoring agents can be included in the oral pharmaceutical compositions. If desired, conventional agents for modifying tastes, colors, and shapes of the special forms can also be included.
• the pharmaceutical compositions can be in lyophilized powder in admixture with suitable excipients in a suitable vial or tube.
• the drugs may be reconstituted by dissolving the lyophilized powder in a suitable solvent system to form a composition suitable for intravenous or intramuscular injection.
• a pharmaceutical composition comprising a therapeutically effective amount of a a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor as well as a therapeutically effective amount of a neuraminidase inhibitor chosen from the group of oseltamivir, oseltamivir phosphate, zenamivir and peramivir.
• the composition can be in an orally administrable form (e.g., tablet or capsule or syrup etc.) with a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to lOOOmg, 0.1 to 500mg, 0.1 to 200mg, 30 to 300mg, 0.1 to 75mg, 0.1 to 30 mg) of a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor and a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to lOOOmg, 0.1 to 500mg, 0.1 to 200mg, 30 to 300mg, 0.1 to 75mg, 0.1 to 30 mg) of neuraminidase inhibitor as described above.
• a therapeutically effective amount e.g., from 0.1 mg to 2000 mg, 0.1 mg to lOOOmg, 0.1 to 500mg, 0.1 to 200mg, 30 to 300mg, 0.1 to 75mg, 0.1
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
• the M EK inhibitor, p38 inhibitor and/or NFKB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the M EK inhibitor, the p38 inhibitor and/or the NFKB inhibitor reduces the bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with a bacterium, when compared to the in vitro test system before the contacting.
• test system comprises cultured cells infected with
• the present invention also provides for an in vitro test system, wherein the in vitro test system comprises cultured cells infected with a bacterium.
• the in vitro test system comprises cultured cells infected with a bacterium.
• these infections can be taking place sequentially or simultaneously.
• a “cultured cell” or “cultured cells” is/are cells, which are not present in their natural environment e.g. within a plant or animal. Rather a cultured cell may be a primary cell culture, which comprises cells isolated from their natural environment, or a cell line. Preferably the cultured cells are human lung epithelial cells.
• the cultured cells are seeded at a density of about 1 xlO 5 , 2 xlO 5 , 3 xlO 5 , 4 xlO 5 , 5 xlO 5 , 6 xlO 5 , 7 xlO 5 , 8xl0 5 , 9xl0 5 , lOxlO 5 ' 11 xl0 5 most preferably 8xl0 5 cells in 0.5 ml, 1 ml, 1.5 ml, 2 ml, 2.5 ml, 3 ml, 3.5 ml, 4 ml medium such as DM EM. Most preferred is a density of 8xl0 5 cells per in 2 ml DM EM .
• Such cultured cells are infected with a virus and a bacterium or in other embodiments with a bacterium alone.
• a co-infection can take place in a sequential or simultaneous manner.
• the cultured cells may be infected first with the influenza virus and 30 minutes later with bacterium/bacteria. It is also possible to additionally add an antibiotic to the culture after 3 hours, to remove extracellular bacteria. In such a scenario the antibioticum would then become washed off again.
• the cells are only infected with a bacterium.
• contacting refers to the bringing of a cell comprising an influenza virus and a bacterium spatially into close proximity to a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor. This can for example mean that an inhibitor is applied to the medium in which the cultured cells are located via a syringe.
• the inhibitor Upon contacting then, if the inhibitor is active, the viral infection as well as the bacterial infection becomes reduced.
• the inhibitor of the present invention is used to reduce only a bacterial infection in the absence of an influence virus infection.
• the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
• plaque forming units (pfu)/ml is a measure of the number of particles capable of forming plaques per unit volume, such as virus particles. It is a functional measurement rather than a measurement of the absolute quantity of particles: viral particles that are defective or which fail to infect their target cell will not produce a plaque and thus will not be counted.
• a solution of influenza virus with a concentration of 1,000 PFU/ ⁇ indicates that 1 ⁇ of the solution contains enough virus particles to produce 1000 infectious plaques in a cell monolayer.
• a cell culture treated with an inhibitor shows a reduced number of plaque forming units in a culture after the treatment, when compared to a culture before the treatment with an inhibor of the present invention.
• a possible "reduction in plaque forming units (pfu)/ml” is analysed in the following way. First the cultured cells, which are co-infected with an influenza virus and a bacterium are analysed for their ability to generate plaque forming units (pfu)/ml by e.g. sucking of some cells from the petridish and plating them for counting the bacterial plaques that will form. This result is then compared to the number of plaque forming units (pfu)/ml generated by cells of the same culture after the inhibitor was applied. If the number of the plaque forming units (pfu)/ml is reduced after the treatment with an inhibitor compared to the number generated before the application of the inhibitor, there is a reduction in the plaque forming units.
• the "colony forming units (CFU)/ml” estimates the number of viable bacteria in a sample. Different methods exist. For example to generate colony forming units a sample (e.g. cultured cells in a small volume) are spread across the surface of a nutrient agar plate and allowed to dry before incubation for counting. A viable bacterium is defined as the ability to multiply via binary fission under the controlled conditions. The visual appearance of a colony in a cell culture requires significant growth - when counting colonies it is uncertain if the colony arose from one cell or 1,000 cells.
• CFU colony forming units
• CFU/ml colony-forming units per milliliter
• CFU/g colony- forming units per gram
• the invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection.
• the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
• the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting.
• the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
• the present invention in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection.
• the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease.
• Item 5 Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting.
• the present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium.
• Item 7 Also provided for is a cultured cell infected with a bacterium.
• the present invention also relates to a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection in a subject, comprising administering a therapeutically effective amount of a M EK inhibitor, a p38 inhibitor and/or a N FKB inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject.
• the present invention provides for a use of a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor of the present invention or a composition of the present invention for the preparation of a medicament.
• the present invention relates to a use of a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
• the present invention also provides for a method for the prophylaxis and/or treatment of a bacterial infection in a subject, comprising administering a therapeutically effective amount of a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject.
• the present invention relates to a use of a M EK inhibitor, a p38 inhibitor and/or a NFKB inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a bacterial infection.
• Human lung epithelial cells were seeded in 6-well plates (8xl0 5 cells/well) in 2 ml DM EM [10%FCS]. 16— 20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCI 2 , 0.9 mM CaCI 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 ⁇ per 6 well) or PBS/BA containing the virus at the indicated multiplicity of infection (MOI) at 37 °C.
• BSA bovine serum albumin
• MOI multiplicity of infection
• DMEM/INV 1% human serum albumin, 25 nmol/l HEPES
• 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DM EM/INVantibiotics [2 ⁇ / ⁇ lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37 °C.
• IV titers are depicted as plaque forming units (pfu)/ml and S. aureus titers are depicted as colonie forming untits (CFU)/ml.
• Data represent the means ⁇ SD of two to three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (* p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001).
• chemokines such as CCL3, also known as macrophage inflammatory protein la (MlPla) and CCL5, also known as RANTES were analysed by qRT-PCR in an infection experiment in presence or absence of U0126 (50 ⁇ ) ( Figure 16A, B).
• CCL3 mRNA synthesis which was increased in presence of S. aureus 6850, was reduced in presence of U0126.
• CCL5 mRNA synthesis which was reduced in presence of S. aureus, was further reduced in presence of U0126 (50 ⁇ ).
• Cobimetinib was tested in an in vivo mouse model, influenza virus-infected mice were left untreated or treated daily with Cobimetinib and were super-infected with S. aureus 6850 (Figure 20).
• the administration of Cobimetinib led to a slight but clearly detectable reduction in viral and bacterial titers in vivo. Since it has been shown recently that the maximal tolerated dose of Cobimetinib is 30mg/kg/day. Thus, the inhibitory effect might be improved by higher dosages than used in the present experiment (lOmg/kg/day), which was far less from the maximal tolerated dosage.
• the results show different MEK inhibitors as potential anti-IAV/S. aureus substances.
• N FKB-inhibitor LG-ASA 5mM
• H 1N 1 The effect of the N FKB-inhibitor LG-ASA (5mM ) against influenza virus replication A/Puerto Rico/8/34 (H 1N 1) was determined in human lung epithelial cells in a singular or co-infection situation ( Figure 22/23) 8h ( Figure 22/23 A, B, E, F) and 18h ( Figure 22/23 C, D, G, H) post infection.
• Two different S. aureus strains were used for infection (a) S. aureusSHlOOO (Figure 22/23 A-D) and (b) S. aureus6850 (Figure 22/23 E-H).
• NFKB was induced by TNF-a stimulation 4 hours prior bacterial infection.
• the activation of NFKB resulted in the enhanced uptake of S. aureus6850 and S. aureusUSA300.
• LG-ASA As a control TN F-a-induced activation was simultaneously blocked by LG-ASA, which resulted in the inhibition of TN F-a-promoted bacterial uptake, as expected ( Figure 25).
• the NF- kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.
• Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. Journal of virology 81, 3058-3067.
• EGFR epidermal growth factor receptor
• the NF- kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral research 99, 336-344.
• Influenza virus primes mice for pneumonia from Staphylococcus aureus. The Journal of infectious diseases 203, 880- 888. '
• Acetylsalicylic acid blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cellular microbiology 9, 1683-1694.
• NF- kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation.
• TRAIL tumor necrosis factor-related apoptosis-inducing ligand

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Virology (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Toxicology (AREA)
• Biochemistry (AREA)
• Biomedical Technology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• General Engineering & Computer Science (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Emergency Medicine (AREA)
• Communicable Diseases (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pulmonology (AREA)
• Food Science & Technology (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=50980349

Family Applications (1)

Country Status (10)

Cited By (12)

Families Citing this family (17)

Citations (15)

Family Cites Families (2)

• 2015
  • 2015-05-18 WO PCT/IB2015/053644 patent/WO2015173788A1/en not_active Ceased
  • 2015-05-18 CA CA2949004A patent/CA2949004A1/en active Pending
  • 2015-05-18 CN CN202310240041.7A patent/CN116942832A/zh active Pending
  • 2015-05-18 AU AU2015260765A patent/AU2015260765B2/en not_active Ceased
  • 2015-05-18 BR BR112016026556A patent/BR112016026556A8/pt not_active Application Discontinuation
  • 2015-05-18 EP EP15726345.0A patent/EP3142658B1/en active Active
  • 2015-05-18 KR KR1020167035245A patent/KR102405136B1/ko active Active
  • 2015-05-18 CN CN201580038887.6A patent/CN107073123A/zh not_active Withdrawn
  • 2015-05-18 CN CN202110506866.XA patent/CN113398271A/zh active Pending
  • 2015-05-18 EA EA201692303A patent/EA039897B1/ru unknown
  • 2015-05-18 US US15/310,836 patent/US10456440B2/en active Active
  • 2015-05-18 JP JP2017512462A patent/JP6818676B2/ja not_active Expired - Fee Related
  • 2015-05-18 EP EP20151682.0A patent/EP3708156A1/en not_active Withdrawn
• 2019
  • 2019-09-16 US US16/571,550 patent/US11135263B2/en not_active Expired - Fee Related
• 2020
  • 2020-10-13 AU AU2020256326A patent/AU2020256326B2/en not_active Ceased
  • 2020-12-28 JP JP2020218254A patent/JP2021059592A/ja active Pending
• 2021
  • 2021-10-01 US US17/492,088 patent/US20220096590A1/en not_active Abandoned
• 2022
  • 2022-11-10 AU AU2022268364A patent/AU2022268364A1/en not_active Abandoned

Patent Citations (18)

Non-Patent Citations (68)

Also Published As

Similar Documents

Legal Events